Dr. Singh on Investigational Immunotherapy Combinations in Urothelial Cancer

Parminder Singh, MD
Published: Friday, Aug 09, 2019



Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses investigational immunotherapy combinations in urothelial cancer.

Combination strategies are emerging, says Singh. At the 2019 ASCO Annual Meeting, Padmanee Sharma, MD, PhD, of The University of Texas MD Anderson Cancer Center, presented data regarding the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in previously treated patients with metastatic disease. The expansion cohort results of the phase I/II CheckMate-032 trial showed that the objective response rate was 38.0% in patients who received 3 mg/kg of nivolumab and 1 mg/kg of ipilimumab.

In addition to combinations of double immunotherapy agents, combinations of immunotherapy and antibody-drug conjugates and chemotherapy are being explored. These combinations may broaden the utility of immunotherapy in the field to targeted agents such as erdafitinib (Balversa) and enfortumab vedotin, says Singh.
SELECTED
LANGUAGE


Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses investigational immunotherapy combinations in urothelial cancer.

Combination strategies are emerging, says Singh. At the 2019 ASCO Annual Meeting, Padmanee Sharma, MD, PhD, of The University of Texas MD Anderson Cancer Center, presented data regarding the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in previously treated patients with metastatic disease. The expansion cohort results of the phase I/II CheckMate-032 trial showed that the objective response rate was 38.0% in patients who received 3 mg/kg of nivolumab and 1 mg/kg of ipilimumab.

In addition to combinations of double immunotherapy agents, combinations of immunotherapy and antibody-drug conjugates and chemotherapy are being explored. These combinations may broaden the utility of immunotherapy in the field to targeted agents such as erdafitinib (Balversa) and enfortumab vedotin, says Singh.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x